- •Risk stratification is a major challenge in patients undergoing TIPS implantation.
- •Age, bilirubin, albumin and creatinine emerged as the most significant predictors of 6-months survival after TIPS implantation.
- •These measures were summarized in a new score named the Freiburg index of post-TIPS survival (FIPS).
- •The FIPS score clearly identifies a high-risk group of patients with a markedly reduced survival after TIPS implantation.
- •Importantly, prognostic discrimination was superior to the MELD, MELD-Na, Child-Pugh score and the bilirubin-platelet model.
Background & Aims
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Procedural and shunt-related complications and mortality of the transjugular intrahepatic portosystemic shunt (TIPSS).Aliment Pharmacol Ther. 2016 Nov; 44: 1051-1061
- Compensated cirrhosis: natural history and prognostic factors.Hepatology. 1987 Jan-Feb; 7: 122-128
- Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients.Aliment Pharmacol Ther. 2014 May; 39: 1180-1193
- A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts.Hepatology. 2000 Apr; 31: 864-871
- A model to predict survival in patients with end-stage liver disease.Hepatology. 2001 Feb; 33: 464-470
- Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by TIPS.J Hepatol. 2011 May; 54: 901-907
- Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites.Gastroenterology. 2017 Jan; 152: 157-163
- Smaller-diameter covered transjugular intrahepatic portosystemic shunt stents are associated with increased survival.Clin Gastroenterol Hepatol. 2019 Dec; 17 (e1): 2793-2799
- Prevention of rebleeding from esophageal varices in patients with cirrhosis receiving small-diameter stents versus hemodynamically controlled medical therapy.Gastroenterology. 2015 Sep; 149 (e1): 660-668
- Transjugular intrahepatic portosystemic shunt using the new Gore viatorr controlled expansion endoprosthesis: prospective, single-center, preliminary experience.Cardiovasc Interv Radiol. 2019 Jan; 42: 78-86
- Prospective evaluation of passive expansion of partially dilated transjugular intrahepatic portosystemic shunt stent grafts-A three-dimensional sonography study.J Vasc Interv Radiol. 2017 Jan; 28: 117-125
- Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial.Lancet Gastroenterol Hepatol. 2019 Aug; 4: 587-598
- Identifying optimal candidates for early TIPS among patients with cirrhosis and acute variceal bleeding: a multicentre observational study.Gut. 2019 Jul; 68: 1297-1310
- Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement.BJOG. 2015 Feb; 122: 434-443
- TIPS: 25 years later.J Hepatol. 2013 Nov; 59: 1081-1093
- MELD-Na as a prognostic indicator of 30- and 90-day mortality in patients with end-stage liver disease after creation of transjugular intrahepatic portosystemic shunt.Eur J Gastroenterol Hepatol. 2015 Oct; 27: 1226-1227
- Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt.Gut. 2003 Jun; 52: 879-885
- Transjugular intrahepatic portosystemic shunt for patients with liver cirrhosis: survey evaluating indications, standardization of procedures and anticoagulation in 43 German hospitals.Eur J Gastroenterol Hepatol. 2020 Sep; 32: 1179-1185
- MELD or sodium MELD: a comparison of the ability of two scoring systems to predict outcomes after transjugular intrahepatic portosystemic shunt placement.AJR Am J Roentgenol. 2020 Jul; 215: 215-222
- Applying the original model for end-stage liver disease score rather than the model for end-stage liver disease-Na score for risk stratification prior to transjugular intrahepatic portosystemic shunt procedures.Eur J Gastroenterol Hepatol. 2020 May 8; (Epub ahead of print)https://doi.org/10.1097/MEG.0000000000001760
- EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.J Hepatol. 2018 Aug; 69: 406-460
- Endothelial dysfunction in the regulation of cirrhosis and portal hypertension.Liver Int. 2012 Feb; 32: 199-213
- Vascular endothelial dysfunction in cirrhosis.J Hepatol. 2007 May; 46: 927-934
- Acute kidney injury in decompensated cirrhosis.Gut. 2013 Jan; 62: 131-137
- Causes of renal failure in patients with decompensated cirrhosis and its impact in hospital mortality.Ann Hepatol. 2012 Jan-Feb; 11: 90-95
- Systematic review: the model for end-stage liver disease--should it replace Child-Pugh's classification for assessing prognosis in cirrhosis?.Aliment Pharmacol Ther. 2005 Dec; 22: 1079-1089
- Application of the model for end-stage liver disease score for transjugular intrahepatic portosystemic shunt in cirrhotic patients with refractory ascites and renal impairment.Eur J Gastroenterol Hepatol. 2004 Jun; 16: 607-612
- Ascites control by TIPS is more successful in patients with a lower paracentesis frequency and is associated with improved survival.JHEP Rep. 2019 May 10; 1: 90-98
- Early TIPS (transjugular intrahepatic portosystemic shunt) cooperative study group. Early use of TIPS in patients with cirrhosis and variceal bleeding.N Engl J Med. 2010 Jun 24; 362: 2370-2379
Author names in bold designate shared co-first authorship